Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis

INTRODUCTION: The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung cancer (NSCLC) with EGFR+ mutations. However, most patients develop resistance, with the result that median progression-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Batson, Sarah, Mitchell, Stephen A, Windisch, Ricarda, Damonte, Elisabetta, Munk, Veronica C, Reguart, Noemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426468/
https://www.ncbi.nlm.nih.gov/pubmed/28503070
http://dx.doi.org/10.2147/OTT.S134382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426468/
https://www.ncbi.nlm.nih.gov/pubmed/28503070
http://dx.doi.org/10.2147/OTT.S134382

Ejemplares similares